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Objective: To identify and prioritize factors associated with an increased risk of developing severe anaphylaxis.  
Methods: Data from the Anaphylaxis Registry (122 centers in 11 European countries) was used in logistic regression models considering existing severity grading systems, elicitors, and symptoms to identify the relative risk of factors on the severity of anaphylaxis.  
Results: We identified higher age and concomitant mastocytosis (OR: 3.1, CI: 2.6 - 3.7) as the most important predictors for an increased risk of severe anaphylaxis. Vigorous physical exercise (OR: 1.5, CI: 1.3 - 1.7), male sex (OR: 1.2, CI: 1.1 - 1.3), and psychological burden (OR: 1.4, CI: 1.2 - 1.6) were more often associated with severe reactions. Additionally, intake of beta-blockers (OR: 1.9, CI: 1.5 - 2.2) and ACE-I (OR: 1.28, CI: 1.05, 1.51) in temporal proximity to allergen exposition were identified as important factors in logistic regression analysis.  
Conclusion: Our data suggest it may be possible to identify patients who require intensified preventive measures due to their relatively higher risk for severe anaphylaxis by considering endogenous and exogenous factors. 
Key words Age, anaphylaxis, logistic regression, mastocytosis, risk factors,   
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Network (NIAID/FAAN) [8] and the Ring and Messmer grading system [9]. The first one divides anaphylactic events into "severe", and "non-severe" cases and the latter one provides four levels of severity (grades I - IV). Although these systems lack specificity, and have not been validated their accessibility makes them widely used in clinical practice in northern America and central Europe. Within the present data analysis we sought to describe and prioritize factors associated with an increased risk of severe anaphylactic reactions to provide a basis for better identification and avoidance of the most important ones in clinical practice. 
Methods 
Database and cohort In this study, the data from the European Anaphylaxis Registry [10] (status for May 2017) was analyzed. Briefly, the registry gathers cases of immediate hypersensitivity reactions reported by trained professionals from 122 centers (of which 47 were pediatric centers) in 11 European countries (Austria, Bulgaria, France, Germany, Greece, Ireland, Italy, Poland, Spain, Slovenia and Switzerland). The online data entry system uses a questionnaire developed by an expert panel [11] and gathers clinical data from medical reports supplemented by patient's history. It covers pseudonymized patients medical data on the symptoms of anaphylaxis, along with the course of treatment and future episodes prophylaxis. The study was approved by the Ethics Committee at Charité - Universitätsmedizin Berlin (the coordinating center) and by the local Ethics Committees in all participating countries. For this analysis, data about factors which can influence the severity of anaphylaxis (i.e. eliciting factors, concomitant diseases, medications, and lifestyle) were used for logistic regression modelling. We limited the cohort to cases meeting the definition of anaphylaxis by NIAID/FAAN [8]. We excluded repeated reactions of patients who had more than one reported reaction to avoid violation of the logistic regression assumptions. Therefore, only the first reported event of anaphylaxis was included in the final database from patients who had multiple reactions. We included eliciting factors in the models and grouped elicitors of anaphylaxis into four categories: food, drug, insect venom, and other elicitors (which consisted of known elicitors not belonging to previous groups and idiopathic elicitors).   










This article is protected by copyright. All rights reserved. 
restricted to only two levels of mild to moderate anaphylaxis (grades II, and III) and severe reactions (grade IV). 2. We included the following predictor variables in the initial models: age, sex, concomitant diseases (rhinitis, asthma, atopic dermatitis, cardiac disorders, mastocytosis, thyroid disorders, infection), concomitant medication (ACE-I, ASA, AT2, beta-blocker), reaction elicitor (restricted to food, insect venom, drugs, and "other"), lifestyle (physical exercise intensity and psychological stress level), and whether it was a first or subsequent anaphylaxis episode in a given patient. 3. We verified that selected predictors were not violating the assumptions of logistic regression i.e. (1) we checked for similar variables closely correlated variables (Cramer's V > 0.25) and included only one of them; (2) excluded variables that may not have the mechanistic role in the severity of anaphylaxis. 4. Generalized linear models of binomial dependent variable were created for NIAID/FAAM and Ring and Messmer (restricted to two levels) severity gradings using the "glm" function from the "stats" package [12]. 5. Models underwent a predictor selection process using step-wise elimination of the non-significant predictors by comparison of the model's calculated Akaike Information Criterion (AIC). 6. We removed the predictors which had a negligible impact to obtain models with minimal sets of predictors, as advised in the SAMPL guidelines [13]. 7. The resulting final models were reported in figures and tables and used for subsequent analyses. The reporting of regression results conforms with the EQUATOR Network's SAMPL Guidelines [13] and includes the recommendations from Peng et al. [14]. We used The R software package for statistical analysis [12]. Variable importance was determined using mean z-values of multiple regression models. We defined statistical significance as α = 0.05. 
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Age is the dominant risk factor for severe anaphylaxis Age was the most important predictor when performing the multivariable analysis (Fig. 2 and 3). Each year was associated with 1.6% (CI: 1.4% - 1.9%) increase in the odds of experiencing a severe anaphylactic event, given that all other variables were held equal (Table 1, S1 and S2). The relation of increasing odds of severe anaphylaxis to age was most evident in the NIAID/FAAN severity grading in patients aged 13-56 years (Fig. 2) and did not follow the linear relationship at age extremes. In the Ring and Messmer grading system patients over 70 years old had significantly more severe reactions (Fig. 2). The age of patients who experienced serious anaphylaxis varied significantly between these models (Ring and Messmer mean age in grade IV cases: 49.96; NIAID/FAAN mean age in severe cases: 42, p-value < 0.0001).  
Male sex Male sex was associated with a higher risk of severe anaphylaxis (OR: 1.16 and 1.92 in NIAID/FAAN and Ring and Messmer grading based models respectively). This represents a consistent finding between both anaphylaxis models (Table 1), although this relationship was not illustrated by a simple Chi2 test (p-value = 0.1187; Table S1).  
Mastocytosis Mastocytosis was a concomitant disease in 120 patients, (1.64% of all cases in our database, tables S1 and S2). Patients with mastocytosis had 1.59 times higher crude (other factors not accounted for) relative risk of developing a more serious anaphylaxis response than non-mastocytosis patients.  Regression models for both severity grading systems revealed that mastocytosis increased the odds of developing severe anaphylaxis. Patients who were diagnosed with mastocytosis had a 3.19, (CI: 2.66 - 3.73) and 5.46, (CI: 4.89 - 6.06) times higher odds for developing more severe anaphylaxis than subjects without indication of mastocytosis (according to the NIAID/FAAN and Ring and Messmer severity grading based regression models). Mastocytosis increased the risk (p < 0.0001) of severe anaphylaxis in the venom-elicited cases.  
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Vigorous exercise The NIAID/FAAN grading system based model included exercise level as an important variable in the selection process. Patients who reported vigorous exercise during (or prior to) a given reaction had a higher risk to develop severe anaphylaxis 1.48, (CI: n1.28 - 1.67) in comparison to non-physically-active patients (reference level). Dissecting this cofactor to the main elicitor groups (food, insects and drugs) the models restricted to drugs and food indicated vigorous exercise to be associated with a higher risk to develop more severe anaphylaxis (OR = 3.5, p value = 0.03 and OR = 2.06, p value = <0.0001 respectively). When the model was restricted to food this risk was corresponding to the level of exercise (higher reported exercise level - higher risk of developing a severe reaction.  
Psychological burden Patients, who in the physician's opinion, had a clinically relevant psychological burden preceding the reaction had a 1.40, (CI: 1.19 - 1.61) times greater odds of developing more severe anaphylaxis than their counterparts (Table 1 and S1).  
Concomitant infection In 257 cases physicians reported an active infection concomitant to anaphylaxis (e.g. upper respiratory tract infection or common cold). 52.14% of these patients had a severe anaphylaxis. Infection failed to be considered significant in any of our models.  
Concomitant asthma The model based on NIAID/FAAN grading indicated that asthmatic patients had a rather lower risk of developing serious anaphylaxis (OR: OR: 0.75, CI: 0.61 - 0.88; table S1). However, this predictor was insignificantly increasing the risk in the Ring and Messmer grading based model (OR = 1.43, (CI: 1.01 - 1.84); p = 0.09).  
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Drugs as elicitors of anaphylaxis were included in both regression models and indicated that, if a reaction was elicited by drugs, the reaction was more likely to be severe (OR: 1.43, CI: 1.23 - 1.62). The values were consistent with these in the Ring and Messmer model. OR: 2.29, (CI: 1.73 - 2.86). These findings suggest that drugs as elicitors of anaphylaxis, though being a non-homogeneous group of elicitors increase the on the severity of a reaction. 
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contribute to the risk of developing a severe anaphylactic response independently from the elicitor. Concomitant drug intake  influence is however not consistent in all the regression models. These factors may play a role in different sub-populations of patients, and additionally, are most likely influenced by the non-heterogeneous group of concomitant diseases (e.g. hypertension, congestive heart failure but also arrhythmia or diabetes) for which these medications are used. On the other hand, it was recently shown that beta-blockers and the ACE-inhibitor ramipril can directly promote mast cell activation [15] and are associated with increased odds for severe anaphylaxis. A limitation of the European Anaphylaxis Registry is the lack of a corresponding control group. Therefore, we cannot draw inferences which factors are increasing the risk of developing anaphylactic responses in general. A potential confounder of the severity of anaphylaxis is the treatment itself, which decreases the severity of the symptoms if administered quickly. This way, an immediately treated patient with a potentially lethal response might be classified as only having milder symptoms due to the prompt administration of epinephrine. Moreover, low number of fatal cases of anaphylaxis in our registry (due to lack of referencing from the emergency departments) may skew the analysis results. The results in NIAID/FAAM and Ring and Messmer based models were similar and slight differences were expected due to non-uniform division of severity grades in these models.  Taken together, our data enabled us for the first time to calculate the relative risk of endogenous and exogenous factors influencing the severity of anaphylaxis based on a large dataset. 
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Tables  
NIAID/FAAM R&M II+III vs. IV 
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Observations 7,316 7,316
Log Likelihood -4,537.394 -779.569 
Akaike Inf. Crit. 9,102.788 1,579.137 
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Table 1: Regression coefficients of the models explaining the severity of anaphylaxis in two severity scales with predictors listed in the columns. The logistic regression coefficients represent the change in logit for each (unit) change in the predictor. Given that the logit is not intuitive we focused on odds ratios (OR) to evaluate the contribution of individual predictors. OR in two different regression models illustrate the association between co-factors of anaphylaxis and: A) NIAID/FAAN definition of anaphylaxis, and B) Ring and Messmer's Anaphylaxis severity scale (logistic regression models). § The predictor was proven insignificant in this model and was therefore excluded by the stepwise predictor selection algorithm.  
 
